SAPT Versus DAPT in Incomplete Revascularization After CABG
ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorCampus Bio-Medico University
About this trial
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG).
Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.
Eligibility criteria
Qualifiers
patients undergoing CABG, ± cardiopulmonary bypass, ± any associated cardiac procedures (valve replacement,...)
incomplete myocardial revascularization, defined by anatomic or functional criteria
obtained informed consent
Disqualifiers
acute coronary syndrome < 12 months from surgery
dual antiplatelet therapy at hospital admission
planned procedure to complete myocardial revascularization (e.g. hybrid approach)
intolerance / unable to take acetylsalicylic acid or ticagrelor
Trial design
Treatments tested in this trial
- Ticagrelor
- acetylsalicylic acid
Treatment groups
800 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov